Characteristics of patients in the GVHD onset analyses (cohorts 1 and 2) and the landmark analysis at 11 to 17 days (day 14 ± 3) after transplantation
. | Cohort 1 onset analysis (n = 74) . | Cohort 2 onset analysis (n = 76) . | Landmark analysis (n = 167) . |
---|---|---|---|
Median age, y (range) | 42 (18-66) | 45 (13-65) | 45 (10-65) |
Median day of GHVD onset (range) | 20 (7-64) | 24 (11-82) | 26 (15-99)* |
Diagnosis, n (%) | |||
Acute leukemia | 38 (51) | 54 (58) | 93 (56) |
Myelodysplastic syndrome | 16 (22) | 20 (26) | 40 (24) |
Lymphoma | 7 (9) | – | 6 (4) |
Chronic myeloid leukemia | 12 (16) | 11 (14) | 25 (15) |
Other diagnosis | 1 (1) | 1 (1) | 3 (2) |
Donor type, n (%) | |||
Related | 33 (45) | 25 (33) | 71 (43) |
Unrelated | 41 (55) | 51 (67) | 96 (57) |
Graft type, n (%) | |||
Marrow | 6 (8) | 16 (21) | 28 (17) |
Peripheral blood | 68 (92) | 60 (79) | 139 (83) |
Sex match, n (%) | |||
Female to male | 17 (23) | 22 (29) | 59 (35) |
Other | 57 (77) | 54 (71) | 108 (65) |
Conditioning regimens, n (%) | |||
Myeloablative | 73 (99) | 76 (100) | 167 (100) |
Reduced intensity | 1 (1) | — | — |
CMV serostatus before transplant (donor/recipient), n (%) | |||
+/+ | 21 (28) | 17 (22) | 38 (23) |
−/+ | 18 (24) | 18 (24) | 38 (23) |
+/− | 8 (11) | 6 (8) | 24 (14) |
−/− | 27 (36) | 35 (46) | 67 (40) |
GVHD prophylaxis, n (%) | |||
Calcineurin inhibitor + methotrexate | 65 (88) | 74 (97) | 156 (93) |
Calcineurin inhibitor + methotrexate + mycophenolate mofetil | 4 (5) | 2 (3) | 7 (4) |
Calcineurin inhibitor + mycophenolate mofetil | 3 (4) | — | 2 (1) |
Other regimens | 2 (3) | — | 2 (1) |
. | Cohort 1 onset analysis (n = 74) . | Cohort 2 onset analysis (n = 76) . | Landmark analysis (n = 167) . |
---|---|---|---|
Median age, y (range) | 42 (18-66) | 45 (13-65) | 45 (10-65) |
Median day of GHVD onset (range) | 20 (7-64) | 24 (11-82) | 26 (15-99)* |
Diagnosis, n (%) | |||
Acute leukemia | 38 (51) | 54 (58) | 93 (56) |
Myelodysplastic syndrome | 16 (22) | 20 (26) | 40 (24) |
Lymphoma | 7 (9) | – | 6 (4) |
Chronic myeloid leukemia | 12 (16) | 11 (14) | 25 (15) |
Other diagnosis | 1 (1) | 1 (1) | 3 (2) |
Donor type, n (%) | |||
Related | 33 (45) | 25 (33) | 71 (43) |
Unrelated | 41 (55) | 51 (67) | 96 (57) |
Graft type, n (%) | |||
Marrow | 6 (8) | 16 (21) | 28 (17) |
Peripheral blood | 68 (92) | 60 (79) | 139 (83) |
Sex match, n (%) | |||
Female to male | 17 (23) | 22 (29) | 59 (35) |
Other | 57 (77) | 54 (71) | 108 (65) |
Conditioning regimens, n (%) | |||
Myeloablative | 73 (99) | 76 (100) | 167 (100) |
Reduced intensity | 1 (1) | — | — |
CMV serostatus before transplant (donor/recipient), n (%) | |||
+/+ | 21 (28) | 17 (22) | 38 (23) |
−/+ | 18 (24) | 18 (24) | 38 (23) |
+/− | 8 (11) | 6 (8) | 24 (14) |
−/− | 27 (36) | 35 (46) | 67 (40) |
GVHD prophylaxis, n (%) | |||
Calcineurin inhibitor + methotrexate | 65 (88) | 74 (97) | 156 (93) |
Calcineurin inhibitor + methotrexate + mycophenolate mofetil | 4 (5) | 2 (3) | 7 (4) |
Calcineurin inhibitor + mycophenolate mofetil | 3 (4) | — | 2 (1) |
Other regimens | 2 (3) | — | 2 (1) |
For the 100 patients who subsequently developed GVHD.